<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249388</url>
  </required_header>
  <id_info>
    <org_study_id>19072886</org_study_id>
    <nct_id>NCT04249388</nct_id>
  </id_info>
  <brief_title>Characteristics of People With Advanced Chronic Obstructive Pulmonary Disease (COPD) - A Multicenter Study</brief_title>
  <acronym>REPORT</acronym>
  <official_title>Rethink Pulmonary Rehabilitation (REPORT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary rehabilitation (PR) is a cornerstone of care for people with COPD. There is robust&#xD;
      evidence that PR improves exercise capacity, enhances health-related quality of life (QoL)&#xD;
      and reduces healthcare utilization. PR is strongly recommended in guidelines for COPD&#xD;
      management. Despite the compelling evidence for its benefits, PR is delivered to less than&#xD;
      30% of people with COPD. Access is particularly challenging, an especially for those with the&#xD;
      most progressed disease stages.&#xD;
&#xD;
      We recently completed a randomized clinical trial, showing that approximately 1.100 patients&#xD;
      annually are offered conventional hospital-based PR during routine consultations in the&#xD;
      Capital Region of Denmark, but at least 700 patients declines participation.&#xD;
&#xD;
      No major cohort studies have been published from people with severe and advanced COPD who opt&#xD;
      out of traditional pulmonary rehabilitation. By establishing such cohort study, objective and&#xD;
      qualitative knowledge from assessments and patient interviews is collected in patients we&#xD;
      have very limited access to and knowledge of. Additionally, the collected data will give a&#xD;
      deeper insight and understanding and possibly enable us to design new delivery models to be&#xD;
      tested in proper study designs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective This cohort study aims to describe and understand differences and similarities in&#xD;
      characteristics among people with severe and advanced COPD who opt-in or opt out of PR&#xD;
      services.&#xD;
&#xD;
      The study includes data from: socio-demographic, anthropometric, physical (function,&#xD;
      activity, muscle strength, balance) characteristics as well as self-reported symptoms of&#xD;
      anxiety, depression, fatigue, pain, lung symptoms, quality of life, sleep-quality, mortality,&#xD;
      hospitaladmissions, length of stay and qualitative patient interviews.&#xD;
&#xD;
      Data from our completed trial study (NCT02667171) will be used as the opt-in PR comparison&#xD;
      cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>COPD Assessment Test (CAT)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in points. Lower score indicates improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test Distance (6MWD)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes i meters. High is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in point. Low score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-Qol (EQ5D)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in Visual analogue scale (VAS). Higher VAS is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in points. Low is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Fatigue Inventory (MFI-20)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassesment)</time_frame>
    <description>Observation of changes in points. Low is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Physical Performance Battery (SPPB)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in point. High is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand-Grip Strength (JAMAR)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in kilo. High is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 seconds sit-to-stand test (30sec-STS)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in repetitions. High is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in point. Low score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions (respiratory and all-cause)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in actual numbers. Low is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital admissions (respiratory and all-cause)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in days. Low is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Out-patient visits</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in actual number. Low is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (respiratory and all-cause)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassesment)</time_frame>
    <description>Observation of changes as number of deaths. Low is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up and Go Test</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment)</time_frame>
    <description>Observation of changes in seconds. Low is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity level (ActivPAL)</measure>
    <time_frame>baseline and 52 weeks reassessment, (potentially 104 weeks reassessment) - Worn by the patients around the clock for 5 days</time_frame>
    <description>Observation of changes in steps per day. High is better</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Decliners of Pulmonary Rehabilitation</arm_group_label>
    <description>No intervention, just observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention, just observation</intervention_name>
    <description>No Intervention, just observation</description>
    <arm_group_label>Decliners of Pulmonary Rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a prospective observational study of patients with COPD who declines participation&#xD;
        in a conventional out-patient hospital-based PR program.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of COPD defined as a ratio of forced expiratory volume at one&#xD;
             second (FEV1) to forced vital capacity &lt; 0.70&#xD;
&#xD;
          -  FEV1 &lt;50%, corresponding to severe or very severe COPD&#xD;
&#xD;
          -  Symptoms equivalent to the Medical Research Council (MRC) from 2 to 5&#xD;
&#xD;
          -  Declines to participate in a conventional out-patient hospital-based PR program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent participation in or recent completion of pulmonary rehabilitation within&#xD;
             the last twelve months.&#xD;
&#xD;
          -  Dementia/ Cognitive impairment or uncontrolled psychiatric illness,&#xD;
&#xD;
          -  An impaired hearing and / or vision which causes the instructions in the assessment is&#xD;
             not understood.&#xD;
&#xD;
          -  language difficulties which causes inability to follow instruction or complete patient&#xD;
             reported outcome measures (PROM.)&#xD;
&#xD;
          -  Any comorbidity that are contraindicated to the assesment protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Suppli Ulrik, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hvidovre University Hospital, Respiratory Department and Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Hansen, PhD</last_name>
    <phone>+45 28946780</phone>
    <email>henrik.hansen.09@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Godtfredsen, MD, PhD</last_name>
    <email>Nina.Skavlan.Godtfredsen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bispebjerg and Frederiksberg University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Copenhagen North West</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Oestergaard, RN</last_name>
      <email>Lisbeth.Marie.Oestergaard@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Hanne Ehlers, Lead RN</last_name>
      <email>hanne.dybdal.ehlers@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Therese Lapperre, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisbeth Oestergaard, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanne Ehlers, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amager and Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Danmark</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Hansen, PhD</last_name>
      <email>henrik.hansen.09@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Nina Godtfredsen, MD, PhD</last_name>
      <email>Nina.Skavlan.Godtfredsen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Henrik Hansen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nina Godtfredsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Suppli Ulrik, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gentofte and Herlev University Hospital</name>
      <address>
        <city>Gentofte</city>
        <state>Hellerup</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torgny Wilcke, MD, PhD</last_name>
      <email>t.wilcke@dadlnet.dk</email>
    </contact>
    <contact_backup>
      <last_name>Mette Rosenberg, RN</last_name>
      <email>Mette.Rosenberg@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Torgny Wilcje, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nordsjaelland University Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Berrill, RN</last_name>
      <email>Anja.Berrill@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Stig Mølsted, PhD</last_name>
      <email>Stig.Moelsted@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Stig Mølsted, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anja Berrill, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital, Hvidovre</investigator_affiliation>
    <investigator_full_name>Henrik Hansen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Proposal for data use should be addressed to Henrik.hansen.09@regionh.dk&#xD;
Data access in Denmark are under very strict juristic data protection law.&#xD;
Any possible access or sharing demands a part application to&#xD;
Danish Data Protection Agency,&#xD;
Ethics Committee of the Capital Region&#xD;
National Health Data Authorities.&#xD;
Only if the applications are approved data will be considered available for sharing. The authors will not be able to support this process and a prolonged process must be expected.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>unresolved</ipd_time_frame>
    <ipd_access_criteria>Please read plan description</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

